within Pharmacolibrary.Drugs.ATC.R;

model R03AC12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.020833333333333332,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 3.8,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.95,
    k12             = 2400,
    k21             = 2400
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AC12</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Salmeterol is a long-acting beta-2 adrenergic agonist (LABA) used as a bronchodilator for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is used in combination with inhaled corticosteroids for asthma and as monotherapy or combination in COPD. Salmeterol is currently approved and widely used for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following inhalation administration.</p><h4>References</h4><ol><li><p>Jessen, S, Becker, V, Rzeppa, S, Backer, V, Bengtsen, KH, Hullstein, I, Dehnes, Y, &amp; Hostrup, M (2021). Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. <i>Drug testing and analysis</i> 13(4) 747–761. DOI:<a href=\"https://doi.org/10.1002/dta.2978\">10.1002/dta.2978</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33210444/\">https://pubmed.ncbi.nlm.nih.gov/33210444</a></p></li><li><p>Anwar, MM, El-Haggar, RS, &amp; Zaghary, WA (2015). Salmeterol Xinafoate. <i>Profiles of drug substances, excipients, and related methodology</i> 40 321–369. DOI:<a href=\"https://doi.org/10.1016/bs.podrm.2015.02.002\">10.1016/bs.podrm.2015.02.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26051688/\">https://pubmed.ncbi.nlm.nih.gov/26051688</a></p></li><li><p>Cazzola, M, Testi, R, &amp; Matera, MG (2002). Clinical pharmacokinetics of salmeterol. <i>Clinical pharmacokinetics</i> 41(1) 19–30. DOI:<a href=\"https://doi.org/10.2165/00003088-200241010-00003\">10.2165/00003088-200241010-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11825095/\">https://pubmed.ncbi.nlm.nih.gov/11825095</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AC12;
